Pradeep Harish

List of Publications by Year
in descending order

10	113	1478505 6	1588992 8
papers	citations	h-index	g-index

11	11	11	182
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Knockdown of Muscle-Specific Ribosomal Protein L3-Like Enhances Muscle Function in Healthy and Dystrophic Mice. Nucleic Acid Therapeutics, 2021, 31, 457-464.	3.6	11
2	Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy. International Journal of Molecular Sciences, 2020, 21, 6059.	4.1	9
3	Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease. Frontiers in Physiology, 2020, 11, 184.	2.8	9
4	Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD). Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1016-1026.	7.3	30
5	Gene Therapy for Oculopharyngeal Muscular Dystrophy. , 2019, , 549-564.		2
6	A pilot study to elucidate effects of artificial selection by size on the zebrafish (Danio rerio) fast skeletal muscle transcriptome. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2019, 233, 65-73.	1.8	3
7	Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy. Human Molecular Genetics, 2019, 28, 1694-1708.	2.9	28
8	Advances in emerging therapeutics for oculopharyngeal muscular dystrophy. Expert Opinion on Orphan Drugs, 2018, 6, 693-701.	0.8	3
9	Nuclear PABPN1 aggregates in OPMD: correlation study and therapy. Neuromuscular Disorders, 2017, 27, S202-S203.	0.6	0
10	Progress on Gene Therapy, Cell Therapy, and Pharmacological Strategies Toward the Treatment of Oculopharyngeal Muscular Dystrophy. Human Gene Therapy, 2015, 26, 286-292.	2.7	18